The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1270 articles
GLP-1 receptor agonists are powerful tools for managing diabetes and obesity, but understanding their potential interactions with other medications is crucial for patient safety and treatment efficacy.
Successfully losing weight with medications like Ozempic and Mounjaro is a significant achievement. However, the journey doesn't end there. This article explores how to maintain your progress and prevent weight regain after discontinuing these powerful GLP-1 receptor agonists.
While GLP-1 agonists offer remarkable weight loss, a new perspective highlights why exercise remains indispensable for long-term success and health benefits, addressing challenges in patient adherence.
Heather Marie lost 55kg managing PCOS and hypothyroidism through lifestyle and magnesium supplementation, avoiding injectables like Ozempic. Here is her story and the medical science behind it.
GLP-1 medications are now available as pills for weight loss, offering a needle-free alternative. This comprehensive guide explores what you need to know before starting, including efficacy, absorption, side effects, and lifestyle considerations.
Discover the seismic shift in obesity medicine as online GLP-1 programs leverage telehealth and advanced medications like semaglutide and tirzepatide to provide accessible, medically supervised weight loss solutions.
While GLP-1 medications offer a powerful new path to weight loss, emerging research reveals an unexpected challenge: intensified social stigma. This article explores the nuances of this phenomenon and its implications for patients.
This comprehensive guide delves into the critical considerations surrounding GLP-1 agonists for weight loss, addressing common concerns about age limits, potential risks, and practical advice for patients.
The U.S. military has spent nearly $726 million on GLP-1 medications since 2021. This article delves into the controversy surrounding this expenditure, examining the obesity crisis within the armed forces and the debate over these weight-loss drugs.
